Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated:  10/2/2017
Retinal Consultants of Arizona
mi
from
Mesa, AZ
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated: 10/2/2017
Retinal Consultants of Arizona
mi
from
Mesa, AZ
Click here to add this to my saved trials
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated:  10/2/2017
Retinal Consultants of Arizona
mi
from
Peoria, AZ
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated: 10/2/2017
Retinal Consultants of Arizona
mi
from
Peoria, AZ
Click here to add this to my saved trials
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated:  10/2/2017
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).
Status: Enrolling
Updated: 10/2/2017
Retinal Consultants of Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Social Worker in an Eye-Care Service
The Impact of a Social Worker in a Glaucoma Eye-Care Service: A Prospective Study
Status: Enrolling
Updated:  10/3/2017
Wills Eye Hospital
mi
from
Philadelphia, PA
Social Worker in an Eye-Care Service
The Impact of a Social Worker in a Glaucoma Eye-Care Service: A Prospective Study
Status: Enrolling
Updated: 10/3/2017
Wills Eye Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
Clinical Trial of Interventions for Visual Loss in Nursing Home Residents
Status: Enrolling
Updated:  10/4/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Study of Interventions to Reduce Disability From Visual Loss in Nursing Home Residents
Clinical Trial of Interventions for Visual Loss in Nursing Home Residents
Status: Enrolling
Updated: 10/4/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
A Phase I Unmasked Study to Investigate the Safety and Tolerability of Subconjunctival Injections of Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
A Phase I Unmasked Study to Investigate the Safety and Tolerability of Subconjunctival Injections of Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Rituximab for Autoimmune Retinopathy
Rituximab for Autoimmune Retinopathy
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Rituximab for Autoimmune Retinopathy
Rituximab for Autoimmune Retinopathy
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
Evaluation of Single Nucleotide Polymorphisms (SNPs) in Patients With and Without Diabetic Macular Edema
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Color Vision as a Measure for Inherited Retinal Diseases
Color Vision as an Outcome Measure for Clinical Trials of Inherited Retinal Degenerations
Status: Enrolling
Updated:  10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Color Vision as a Measure for Inherited Retinal Diseases
Color Vision as an Outcome Measure for Clinical Trials of Inherited Retinal Degenerations
Status: Enrolling
Updated: 10/5/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Status: Enrolling
Updated:  10/6/2017
Johns Hopkins University
mi
from
Baltimore, MD
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Status: Enrolling
Updated: 10/6/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated:  10/6/2017
ORA Inc
mi
from
Andover, MA
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of Cetirizine 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated: 10/6/2017
ORA Inc
mi
from
Andover, MA
Click here to add this to my saved trials
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  10/9/2017
The Children's Hospital of Philadelphia (CHOP)
mi
from
Philadelphia, PA
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 10/9/2017
The Children's Hospital of Philadelphia (CHOP)
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated:  10/9/2017
Moorfields Eye Hospital
mi
from
London,
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension
Status: Enrolling
Updated: 10/9/2017
Moorfields Eye Hospital
mi
from
London,
Click here to add this to my saved trials
How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?
Prospective Evaluation of the New Micropulse Transscleral Cyclophotocoagulation
Status: Enrolling
Updated:  10/9/2017
Wills Eye Institute, Glaucoma Service
mi
from
Philadelphia, PA
How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?
Prospective Evaluation of the New Micropulse Transscleral Cyclophotocoagulation
Status: Enrolling
Updated: 10/9/2017
Wills Eye Institute, Glaucoma Service
mi
from
Philadelphia, PA
Click here to add this to my saved trials
The Detection of Glaucoma Using Pupillography
The Detection of Glaucoma Using Pupillography
Status: Enrolling
Updated:  10/10/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
The Detection of Glaucoma Using Pupillography
The Detection of Glaucoma Using Pupillography
Status: Enrolling
Updated: 10/10/2017
Wilmer Eye Institute, Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated:  10/11/2017
ORA Inc
mi
from
Andover, MA
A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis
Status: Enrolling
Updated: 10/11/2017
ORA Inc
mi
from
Andover, MA
Click here to add this to my saved trials
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death
Status: Enrolling
Updated:  10/13/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death
Status: Enrolling
Updated: 10/13/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Ocular Surface Immune Response in Dry Eye Disease
Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation
Status: Enrolling
Updated:  10/16/2017
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Ocular Surface Immune Response in Dry Eye Disease
Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation
Status: Enrolling
Updated: 10/16/2017
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Translation of Eye Movement Reading Training to Clinical Practice
Translation of Eye Movement Reading Training to Clinical Practice
Status: Enrolling
Updated:  10/17/2017
Jesse Brown VA Medical Center, Chicago, IL
mi
from
Chicago, IL
Translation of Eye Movement Reading Training to Clinical Practice
Translation of Eye Movement Reading Training to Clinical Practice
Status: Enrolling
Updated: 10/17/2017
Jesse Brown VA Medical Center, Chicago, IL
mi
from
Chicago, IL
Click here to add this to my saved trials
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated:  10/17/2017
Andover Eye Associates
mi
from
Andover, MA
A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome
Status: Enrolling
Updated: 10/17/2017
Andover Eye Associates
mi
from
Andover, MA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
The Private Practice of Milton Hom, OD
mi
from
Azusa, CA
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
The Private Practice of Milton Hom, OD
mi
from
Azusa, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Havana Research Institute LLC
mi
from
Burbank, CA
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Havana Research Institute LLC
mi
from
Burbank, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Lugene Eye Institute
mi
from
Glendale, CA
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Lugene Eye Institute
mi
from
Glendale, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Eric M. White, OD, INC
mi
from
San Diego, CA
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Eric M. White, OD, INC
mi
from
San Diego, CA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Moyes Eye Center, PC
mi
from
Kansas City, MO
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Moyes Eye Center, PC
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Rochester Ophthalmological Group
mi
from
Rochester, NY
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Rochester Ophthalmological Group
mi
from
Rochester, NY
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Charlotte Eye Ear Nose
mi
from
Charlotte, NC
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Charlotte Eye Ear Nose
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Scott and Christie and Associate
mi
from
Cranberry Township, PA
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Scott and Christie and Associate
mi
from
Cranberry Township, PA
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Texan Eye
mi
from
Austin, TX
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Texan Eye
mi
from
Austin, TX
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Department of Optometry & Vision Sciences, The University of Melbourne
mi
from
Parkville,
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Department of Optometry & Vision Sciences, The University of Melbourne
mi
from
Parkville,
Click here to add this to my saved trials
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated:  10/18/2017
Ophthalmology Associates
mi
from
Saint Louis, MO
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.
A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease
Status: Enrolling
Updated: 10/18/2017
Ophthalmology Associates
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Arcadia, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Arcadia, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Winter Haven, FL
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Winter Haven, FL
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
New Albany, IN
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
New Albany, IN
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Boston, MA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Rapid City, SD
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Study Site
mi
from
Mobile, AL
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Study Site
mi
from
Mobile, AL
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site 1
mi
from
Phoenix, AZ
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site 1
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site 1
mi
from
Tucson, AZ
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site 1
mi
from
Tucson, AZ
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Bakersfield, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Beverly Hills, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Encino, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Encino, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Study Site
mi
from
Los Angeles, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Study Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Mountain View, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Mountain View, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Oceanside, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site 1
mi
from
Palm Desert, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site 1
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Palo Alto, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Poway, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Poway, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Redlands, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Redlands, CA
Click here to add this to my saved trials
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  10/18/2017
Regeneron Investigational Site
mi
from
Sacramento, CA
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 10/18/2017
Regeneron Investigational Site
mi
from
Sacramento, CA
Click here to add this to my saved trials